A composition patent protecting combinations of Biotec Pharmacon’s proprietary compound soluble yeast beta-glucan (SBG) as an adjuvant together with monoclonal antibodies for treatment of cancer has been granted in the U.S.

Biotec Phamacon will present its report for Q1 2010 on May 11th at 09:00. The presentation will be held at Thon Conference Vika Atrium, Oslo. The presentation will also be available as webcast.

The Board of Directors has today given notice of ordinary general meeting in Biotec Pharmacon to be held May 4th, 2010, at 15:00. The meeting will be held at the company's premises in Strandgata 3, Tromsø, Norway.